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The ethics of innovative surgical approaches for
well-established procedures
James W. Jones, MD, PhD, MHA,a Laurence B. McCullough, PhD,a and Bruce W. Richman, MA,bHouston, Tex; and Columbia, MoA surgeon with extensive experience in minimally
invasive robotic procedures plans to use the robotic
apparatus to treat a large splenic artery aneurysm. The
patient is thin but otherwise in good health, and wel-
comes the prospect of less scarring, faster recovery time,
and less pain and suffering than he might experience
with the standard open procedure. He is furthermore
eager to be among the first to receive this innovative
operation. What special ethical obligations might the
surgeon have when replacing a well-established opera-
tion with a new technological approach?
A. He should provide an especially detailed description of
the operation during the informed consent process,
stressing that he has not used the robotic device to treat
this condition before.
B. He should observe the provisions of Option A, and send
a note to the Chief of Surgery about his intentions.
C. He should observe the provisions of Option A, and ask
the Chief of Surgery to convene an ad hoc committee
to consider a formal written plan of the proposed
operation.
D. He should provide the patient a generalized description
of the operation he is planning. Technical details that
could confuse or agitate the patient should be avoided.
E. He should obtain prior approval from his institutional
review board (IRB) and ethics committee.
Repetition and experience are essential to the refine-
ment of surgical skills; intellectual and technical mastery are
accumulated during repeated performances. Even in the
best hands, optimization of results awaits sufficient experi-
ence, or ascension of the surgeon’s learning curve, while he
refines new skills at the expense of early patients. In an
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further along in their laparoscopic experience had signifi-
cantly shorter operating time, lower conversion and com-
plication rates, and patients with shorter postoperative
hospital stays than surgeons who were early in their laparo-
scopic experience.1 The learning curve is necessarily at its
lowest point when any important element of the procedure
is being performed for the first time. Although the learning
curve is an unavoidable influence upon the surgical risk/
benefit ratio, the profession and the individual surgeon are
confronted with the potentially conflicting imperatives of
ensuring that high standards of care be maintained early
and late in the experiential process; that no patient is placed
at increased risk, particularly unknowingly; and that the novel
procedure is selected because it offers some special benefit
to the patient, not just an opportunity for the surgeon to
exercise his adventurous spirit or pad his case series.
The surgeon’s autonomy is regulated in direct propor-
tion to the degree to which the outcome of elective surgery
is uncertain.2 When positive outcomes are effectively cer-
tain, the surgeon may select techniques, instruments, ma-
terials, and even procedural approaches from a standard
armamentarium without prior peer review or other permis-
sion beyond the patient’s standard procedural informed
consent, without explaining such details. These decisions
are based on each patient’s condition, indications, and the
surgeon’s preference for the familiar and routinely reliable
medications and materials of prior experience. The patient
provides informed consent for surgical treatment of a des-
ignated condition. If the procedural method is unusual, as
with new applications of robotic minimally invasive surgery,
then it, too, is likely to be specified in the written consent
narrative, with special risks and benefits so designated.
When emergencies, additional pathology, or other unantic-
ipated intraoperative findings or events require interven-
tions not described during the informed consent process,
the surgeon is compelled to autonomously proceed on the
clinically indicated course. Of course, the surgeon is ethi-
cally obligated to subsequently explain his intraoperative
case management to the patient or surrogate, including
significant errors and complications, as well as the postop-199
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employed to manage such exigencies, they are within the
bounds of ethical clinical care.
Tailoring surgical therapy to a case involving a rare
condition for which there is no standard treatment may be
viewed as experimental, particularly because the outcome is
unpredictable. Nevertheless, its intent is clinical rather than
scientific, since it is unlikely that the condition will again be
encountered and there is no intent to develop a systematic
body of data from which to make scientific extrapolations.3
Treating a single unique patient may or may not entail
greater risks than treating patients with common diseases,
but the former will never constitute a learning curve. Sur-
gical autonomy in clinical therapy of these very rare diseases
is therefore limited only to the constraints inherent in the
informed consent process.
Clinical research clearly limits the surgeon’s autonomy
and imposes additional ethical and legal obligations. To
ensure the scientific integrity of the research, as well as the
safety of patients who become research subjects, the sur-
geon-investigator is ethically and legally obligated to seek
and accept professional oversight, concurrence, critical out-
come analysis, and restricted discretionary authority. The
“Common Rule,” the federal regulation that governs hu-
man subjects research, defines research as “a systematic
investigation, including research development, testing and
evaluation, designed to develop or contribute to generaliz-
able knowledge.”4 Clinical innovation thus becomes re-
search when an intervention is undertaken in conformity
with a scientific protocol intended to widen the body of
medical knowledge and put it into general application. As a
clinical endeavor becomes research, conducted within a
systematic effort to acquire knowledge, regulations require
a detailed advance written plan, conformity with scientific
method, approval by an IRB, and the patient’s detailed
informed consent for research participation.
Our innovating surgeon is planning to transform a
standard operation into an experimental one by radically
revising its methodology. Because he has not performed
this particular robotic operation before, the outcome is
unpredictable and potentially bad. If successful, the opera-
tion may be reported in the literature, repeated by this or
other surgeons, or become recognized as one of a small
series of minimally invasive splenic artery aneurysm exclu-
sions. The procedure, nevertheless, does not meet standard
definitions of research for which advance approval by an
IRB is required. This is not a controlled study with a
standardized protocol, and an enrollment yielding statisti-
cally significant conclusions cannot reasonably be planned
at this time; this case will have to be approached as individ-
ual clinical therapy.
Ineligibility for IRB review as a structured scientific
study eliminates Option E as an ethical guide, but the
proposed procedure remains an elective experimental inno-
vation. It may be argued that application of the minimally
invasive technique to a standard procedure merely merges
two established approaches and should therefore be con-
sidered neither experimental nor especially risk-laden. Thisview would make Option D entirely satisfactory to fulfill the
surgeon’s ethical obligations, but it fails because it obscures
the substantial distinctions that still exist between this
robotic minimally invasive surgery and other more exten-
sively used and refined laparoscopic techniques. The first
proponents of laparoscopic cholecystectomy used similar
arguments to minimize the difficulties of learning the dis-
tinctly different surgical skills required by the new method,
and a clinical fiasco ensued. Surgeons who had long ago
mastered open cholecystectomies were encouraged to em-
brace the new technology before they were adequately trained
in it, and the increased rates of bile duct injuries inflicted on
early patients were cruel reminders of the unforgiving princi-
ples of the learning curve. Robotic surgery shares some termi-
nology and some techniques with the better-established lapa-
roscopic operations, but its routine mastery within the
profession is still years in the future, particularly for yet-
untried applications. The responsible use of the robotic
equipment requires extensive training and repetitive prac-
tice under experienced guidance and well-controlled con-
ditions. Facility is unlikely to be achieved at a weekend
manufacturer’s course.
As the most procedurally oriented of the medical spe-
cialties, surgery has been the most affected by a profession-
wide laxity in defining the characteristics distinguishing
new clinical therapies and structured scientific research.
Major advances in surgical methodology have seldom been
produced by the sort of well-planned, large-sample, closely
controlled studies with which new drugs are routinely
tested for safety and efficacy in advance of general availabil-
ity. New operative techniques have historically had little or
no regulation.5 Many of the major advances in surgery have
been the products of serendipity or desperate measures, and
the slow deliberative scientific process which works well in
drug trials is simply a poor fit in surgery. McKneally and
Daar6 have concluded that this mismatch suggests the need
for a new paradigm to protect scientific integrity, the sur-
gical professions, and surgical patients. Experimental inno-
vation in surgery that does not meet the other specialties’
criteria for controlled research should nonetheless be an-
swerable to the same ethical obligations and procedural
safeguards accepted by our nonsurgical colleagues.
Option A is a good start and would suffice if the procedure
were a single event never to be repeated. Option B adds the
notification of a nominally controlling authority, but neither
closely describes the proposed event nor invites critical
evaluation of its many causes for concern. Option D de-
scribes what we fear is the current practice, giving patients
little indication of their status as experimental subjects.
Option C proposes a method of thoughtful oversight
that has not heretofore been widely applied in surgery but
meets the needs of the profession that fall between com-
plete absence of peer review and the IRB’s traditional role
as arbiter of study protocols with clearly delineated hypoth-
eses, large samples of homogeneous subjects, and rigor-
ously standardized procedures. Option C provides the pa-
tient with all the normal protections of the informed
consent process, and supports them with a written plan to
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adds the expert evaluative functions otherwise met by an
IRB to ensure the proposal’s medical and scientific plausi-
bility, the adequacy of patient safeguards, and the legiti-
macy of its clinical rationale. The review by actual peers
facilitates the surgeon’s goal of providing good care, while
fulfilling the surgical profession’s ultimate ethical duty to
protect the patients entrusted to its care. Requiring a formal
review of peers before embarking on an experimental pro-
cedure necessitates a review of the literature. If our surgeon
were to research the subject, he would find reports of
splenic artery aneurysms being treated with minimally in-
vasive techniques both by exclusion and resection.7-9
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